Advances in research on potential inhibitors of multiple myeloma

Guoyuan Tang; Shan Huang; Ji Luo; Yingmiao Wu; Shuai Zheng; Rongsheng Tong; Ling Zhong; Jianyou Shi

doi:10.1016/j.ejmech.2023.115875

Advances in research on potential inhibitors of multiple myeloma

Eur J Med Chem. 2023 Dec 15:262:115875. doi: 10.1016/j.ejmech.2023.115875. Epub 2023 Oct 17.

Authors

Guoyuan Tang¹, Shan Huang², Ji Luo³, Yingmiao Wu³, Shuai Zheng³, Rongsheng Tong⁴, Ling Zhong⁵, Jianyou Shi⁶

Affiliations

¹ State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China.
² Cancer Center, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, 610072, China.
³ Sichuan Provincial Key Laboratory for Human Disease Gene Study, Center for Medical Genetics, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, 610072, China.
⁴ State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China; Department of Pharmacy, Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, 610072, China. Electronic address: tongrs@126.com.
⁵ Sichuan Provincial Key Laboratory for Human Disease Gene Study, Center for Medical Genetics, Sichuan Academy of Medical Sciences & Sichuan Provincial People's Hospital, University of Electronic Science and Technology of China, Chengdu, Sichuan, 610072, China; Chengdu Institute of Biology, Chinese Academy of Sciences, Chengdu, Sichuan, 610044, China. Electronic address: zhonglingr@126.com.
⁶ State Key Laboratory of Southwestern Chinese Medicine Resources, Chengdu University of Traditional Chinese Medicine, Chengdu, 611137, China; Department of Pharmacy, Personalized Drug Therapy Key Laboratory of Sichuan Province, Sichuan Provincial People's Hospital, School of Medicine, University of Electronic Science and Technology of China, Chengdu, Sichuan, 610072, China. Electronic address: shijianyoude@126.com.

PMID: 37879169
DOI: 10.1016/j.ejmech.2023.115875

Abstract

Multiple myeloma (MM) is a common hematological malignancy. Although recent clinical applications of immunomodulatory drugs, proteasome inhibitors and CD38-targeting antibodies have significantly improved the outcome of MM patient with increased survival, the incidence of drug resistance and severe treatment-related complications is gradually on the rise. This review article summarizes the characteristics and clinical investigations of several MM drugs in clinical trials, including their structures, mechanisms of action, structure-activity relationships, and clinical study progress. Furthermore, the application potentials of the drugs that have not yet entered clinical trials are also reviewed. The review also outlines the future directions of MM drug development.

Keywords: Drug resistance; Multiple myeloma; Potential drugs; Structure-activity relationships.

Publication types

Review

MeSH terms

Antibodies, Monoclonal / therapeutic use
Hematologic Neoplasms* / drug therapy
Humans
Immunomodulating Agents
Multiple Myeloma* / drug therapy
Multiple Myeloma* / pathology
Proteasome Inhibitors / pharmacology
Proteasome Inhibitors / therapeutic use

Substances

Proteasome Inhibitors
Antibodies, Monoclonal
Immunomodulating Agents